- Conditions
- Tinnitus, Subjective
- Interventions
- OTO-313, Placebo
- Drug
- Lead sponsor
- Otonomy, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 16
- States / cities
- Los Angeles, California • San Diego, California • Colorado Springs, Colorado + 13 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1321–1344
of 4,216
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Uveitis
- Interventions
- Placebo, Dose 1 gevokizumab, Dose 2 gevokizumab
- Drug
- Lead sponsor
- XOMA (US) LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 52
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Beverly Hills, California + 49 more
- Conditions
- Multiple Sclerosis
- Interventions
- Methylprednisolone, ACTH, IV placebo, IM placebo
- Drug · Other
- Lead sponsor
- Neurologique Foundation, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Ponte Vedra, Florida
- Conditions
- Shock, Hemorrhagic, Shock, Traumatic, Shock, Septic
- Interventions
- Polydatin Injectable
- Drug
- Lead sponsor
- Neptunus Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Newark, Delaware
- Conditions
- HIV -1 Infection
- Interventions
- BNT351, Placebo
- Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Baltimore, Maryland • St Louis, Missouri + 1 more
- Conditions
- Androgen Deprivation Therapy, Prostate Cancer, Hypertension, Autonomic Dysfunction, Renal Disease
- Interventions
- Gonadotropin Releasing Hormone Agonists (GNRH), Androgen receptor (AR) inhibitor, Placebo
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 40 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- SARS-CoV-2, Influenza
- Interventions
- mRNA-1083, Placebo, Influenza Vaccine, COVID-19 Vaccine
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 8,061 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 146
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Cullman, Alabama + 122 more
- Conditions
- Scar
- Interventions
- Dysport (abobotulinumtoxinA), Bacteriostatic 0.9% Sodium Chloride (vehicle)
- Drug
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio • Westlake, Ohio
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- barzolvolimab, Matching Placebo
- Biological · Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 10 more
- Conditions
- Osteoporosis in Men
- Interventions
- Romosozumab, Placebo
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 55 Years to 90 Years · Male only
- Enrollment
- 245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 3
- States / cities
- Lakewood, Colorado • Bethesda, Maryland • Albuquerque, New Mexico
- Conditions
- Malaria
- Interventions
- PfSPZ Vaccine, PfSPZ (7G8) Challenge, Sodium Chloride, 0.9%
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Obesity; Overweight
- Interventions
- ROSE-010 99 mcg, Placebo, ROSE-010 150 mcg
- Drug
- Lead sponsor
- Rose Pharma Inc
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- COVID-19, SARS-CoV-2
- Interventions
- AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort), Placebo (Parent study Main Cohort), AZD3152 (Sub-study), AZD7442 - EVUSHELD™ (Sub-study), AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 130 Years
- Enrollment
- 3,882 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 130
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Natrunix, Placebo
- Drug
- Lead sponsor
- XBiotech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 243 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 26
- States / cities
- Covina, California • Encino, California • Rancho Mirage, California + 19 more
- Conditions
- Peanut Allergy, Multi-food Allergy
- Interventions
- Omalizumab, Placebo for Omalizumab, Multi-Allergen Oral Immunotherapy, Placebo for Multi-Allergen Oral Immunotherapy, Double-Blind Placebo-Controlled Food Challenge Based Treatment
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 1 Year to 55 Years
- Enrollment
- 458 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • Stanford, California • Denver, Colorado + 7 more
- Conditions
- Cocaine Dependence, Alcohol Dependence
- Interventions
- VIVITROL (Naltrexone extended-release injectable suspension), Placebo
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hidradenitis Suppurativa
- Interventions
- adalimumab, Placebo
- Biological · Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Bakerfield, California • Los Angeles, California + 15 more
- Conditions
- Colitis, Ulcerative
- Interventions
- Vedolizumab 300 mg IV, Placebo IV, Vedolizumab 108 mg SC, Placebo SC
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 383 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 28
- States / cities
- Little Rock, Arkansas • Wheat Ridge, Colorado • Middletown, Connecticut + 25 more
- Conditions
- HIV Infections
- Interventions
- GSK1265744 Tablets, Injectable GSK1265744, Placebo for GSK1265744 Tablets, Injectable Placebo for GSK1265744
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 199 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 4
- States / cities
- Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 1 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- LY3053102, Exenatide ER, Placebo, Metformin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 5
- States / cities
- Orange, California • Miami, Florida • Orlando, Florida + 2 more
- Conditions
- Overweight or Obesity and Elevated Liver Fat
- Interventions
- Maridebart cafraglutide, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 23
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 17 more
- Conditions
- ACE Inhibitor Induced Angioedema
- Interventions
- ecallantide 60 mg, ecallantide 30 mg, ecallantide 10 mg, placebo, placebo match for 30 mg ecallantide arm, placebo match for 10 mg ecallantide arm
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 39
- States / cities
- Montgomery, Alabama • Colton, California • Los Angeles, California + 33 more
- Conditions
- Alpha 1-Antitrypsin Deficiency
- Interventions
- Belcesiran, Placebo
- Drug · Other
- Lead sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- La Jolla, California • Gainesville, Florida • Charleston, South Carolina
- Conditions
- Keloid
- Interventions
- STP705, Placebo
- Drug · Other
- Lead sponsor
- Sirnaomics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Aventura, Florida • Hackensack, New Jersey